Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: <i>In Vitro-In Vivo</i> Study of Vildagliptin as a Model Drug

<div>Successive fractional dissolution time (<svg height="12.1854pt" id="M38" style="vertical-align:-3.37987pt" version="1.1" viewbox="-0.0498162 -8.80553 23.9811 12.1854" width="23.9811pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M655 676H628C608 656 600 650 571 650H156C118 650 114 651 102 676H77C63 615 45 548 24 485L60 486C81 531 97 562 114 580C134 603 148 611 252 611H308L217 127C201 41 196 38 105 32L98 0H384L393 32C300 38 288 41 304 127L393 611H466C553 611 571 604 582 580C592 559 597 530 595 485L630 489C636 548 645 624 655 676Z" id="g50-85"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="673" vert-adv-y="673"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,7.28,3.001)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z" id="g50-51"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,11.712,3.001)"><path d="M158 548H390L417 615L410 623H122L83 318C105 326 143 337 185 337C296 337 350 275 350 188C350 116 308 42 225 42C164 42 122 74 100 93C90 101 82 99 72 92C60 82 51 68 50 59C48 46 52 38 66 24C82 9 125 -12 172 -12C225 -11 292 15 346 59C408 108 437 166 437 226C437 309 371 397 242 397C214 397 170 382 133 369L158 548Z" id="g50-54"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,16.177,3.001)"><path d="M611 626L575 651L170 -9L204 -35L611 626ZM200 635C93 635 50 532 50 449C50 365 94 264 199 264C306 264 349 365 349 450C349 534 304 635 200 635ZM199 601C264 601 273 501 273 450S264 298 200 298C139 298 126 398 126 450S139 601 199 601ZM590 359C485 359 440 256 440 173C440 89 485 -12 589 -12C694 -12 738 89 738 173C738 256 694 359 590 359ZM589 325C653 325 662 225 662 173C662 124 653 22 590 22C529 22 516 122 516 174C516 227 529 325 589 325Z" id="g58-35"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="786" vert-adv-y="786"></glyph.data></g></svg>, <svg height="12.1854pt" id="M39" style="vertical-align:-3.37987pt" version="1.1" viewbox="-0.0498162 -8.80553 23.9811 12.1854" width="23.9811pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M655 676H628C608 656 600 650 571 650H156C118 650 114 651 102 676H77C63 615 45 548 24 485L60 486C81 531 97 562 114 580C134 603 148 611 252 611H308L217 127C201 41 196 38 105 32L98 0H384L393 32C300 38 288 41 304 127L393 611H466C553 611 571 604 582 580C592 559 597 530 595 485L630 489C636 548 645 624 655 676Z" id="g50-85"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="673" vert-adv-y="673"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,7.28,3.001)"><path d="M158 548H390L417 615L410 623H122L83 318C105 326 143 337 185 337C296 337 350 275 350 188C350 116 308 42 225 42C164 42 122 74 100 93C90 101 82 99 72 92C60 82 51 68 50 59C48 46 52 38 66 24C82 9 125 -12 172 -12C225 -11 292 15 346 59C408 108 437 166 437 226C437 309 371 397 242 397C214 397 170 382 133 369L158 548Z" id="g50-54"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,11.712,3.001)"><path d="M245 635C92 635 37 457 37 312C37 149 91 -12 244 -12C395 -12 449 166 449 312C449 469 395 635 245 635ZM243 598C332 598 358 454 358 312C358 173 334 26 245 26C158 26 128 174 128 313S152 598 243 598Z" id="g50-49"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,16.177,3.001)"><path d="M611 626L575 651L170 -9L204 -35L611 626ZM200 635C93 635 50 532 50 449C50 365 94 264 199 264C306 264 349 365 349 450C349 534 304 635 200 635ZM199 601C264 601 273 501 273 450S264 298 200 298C139 298 126 398 126 450S139 601 199 601ZM590 359C485 359 440 256 440 173C440 89 485 -12 589 -12C694 -12 738 89 738 173C738 256 694 359 590 359ZM589 325C653 325 662 225 662 173C662 124 653 22 590 22C529 22 516 122 516 174C516 227 529 325 589 325Z" id="g58-35"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="786" vert-adv-y="786"></glyph.data></g></svg>, MDT, and <svg height="12.1854pt" id="M40" style="vertical-align:-3.37987pt" version="1.1" viewbox="-0.0498162 -8.80553 23.9811 12.1854" width="23.9811pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M655 676H628C608 656 600 650 571 650H156C118 650 114 651 102 676H77C63 615 45 548 24 485L60 486C81 531 97 562 114 580C134 603 148 611 252 611H308L217 127C201 41 196 38 105 32L98 0H384L393 32C300 38 288 41 304 127L393 611H466C553 611 571 604 582 580C592 559 597 530 595 485L630 489C636 548 645 624 655 676Z" id="g50-85"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="673" vert-adv-y="673"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,7.28,3.001)"><path d="M253 635C142 635 71 555 71 471C71 401 113 353 178 316C144 294 106 267 91 252C70 231 46 202 46 157C46 51 132 -12 241 -12C328 -12 442 52 442 168C442 257 379 305 311 343C354 373 380 398 388 407C406 428 417 458 417 487C417 568 348 635 253 635ZM240 600C288 600 340 563 340 481C340 423 313 387 279 360C207 394 148 427 148 499C148 549 182 600 240 600ZM252 23C188 23 129 73 129 163C129 217 162 266 211 298C289 260 360 217 360 144C360 69 312 23 252 23Z" id="g50-57"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,11.712,3.001)"><path d="M245 635C92 635 37 457 37 312C37 149 91 -12 244 -12C395 -12 449 166 449 312C449 469 395 635 245 635ZM243 598C332 598 358 454 358 312C358 173 334 26 245 26C158 26 128 174 128 313S152 598 243 598Z" id="g50-49"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,16.177,3.001)"><path d="M611 626L575 651L170 -9L204 -35L611 626ZM200 635C93 635 50 532 50 449C50 365 94 264 199 264C306 264 349 365 349 450C349 534 304 635 200 635ZM199 601C264 601 273 501 273 450S264 298 200 298C139 298 126 398 126 450S139 601 199 601ZM590 359C485 359 440 256 440 173C440 89 485 -12 589 -12C694 -12 738 89 738 173C738 256 694 359 590 359ZM589 325C653 325 662 225 662 173C662 124 653 22 590 22C529 22 516 122 516 174C516 227 529 325 589 325Z" id="g58-35"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="786" vert-adv-y="786"></glyph.data></g></svg>) of different formulations, respectively.</div>

Journal of Drug Delivery

fig6

Figure 6

Figure 6: Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: <i>In Vitro-In Vivo</i> Study of Vildagliptin as a Model Drug 

Figure 6 | Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: In Vitro-In Vivo Study of Vildagliptin as a Model Drug 